Non-analgesic effects of opioids: Factors relevant to opioid abuse and abuse- deterrent formulations

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6109-6115

  Pergolizzi, Joseph V ^a,b,c,e   Raffa, Robert B ^d   Pergolizzi, Jason S ^e   Taylor, Robert ^e  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^e NEMA Research   (United States)

Author keywords

Abuse deterrent opioids; Abuse resistant opioids; Opioid abuse; Opioid misuse; Opioids

Indexed keywords

OPIATE;

ABUSE DETERRENT FORMULATION; ARTICLE; DRUG FORMULATION; DRUG MONITORING; EUPHORIA; HUMAN; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84873943043     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582379     Document Type: Article

References (58)

1. Sapienza F. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend 2006; 83S: S23-S30.
2. Schneider J, Matthews M, Jamison R. Abuse-deterrent and tamperresistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010; 24(10): 805-10.
3. Katz N, Adams E, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007; 23: 648-60.
4. Monahan G. Drug use/misuse among health professionals. Subst Use Misuse 2003; 38: 1877-81.
5. Gastfriend D. Physician substance abuse and recovery: what does it mean for physicians--and for everyone else? JAMA 2005; 293: 1513-5.
6. Darke S, Mills K, Ross J, Williamson A, Harvard A, Teesson M. The ageing heroin user: career length, clinical profile and outcomes across 36 months. Drug Alcohol Rev 2009; 28(3): 243-9.
7. Anon. Polydrug admissions: 2002. Washington, DC: Substance Abuse and Mental Health Services Administration; 2005 [updated May 16, 2008; cited 2011 13 April]; Available from: http://oas.samhsa.gov/2k5/polydrugTX/polydrugTX.htm.
8. Adlaf E, Smart R. Party subculture or dens of doom? An epidemiological study of rave attendance and drug use patterns among adolescent students. J Psychoactive Drugs 1997; 29(2): 193-8.
9. Rome E. It's a rave new world: rave culture and illicit drug use in the young. Cleveland Clin J Med 2001; 68(6): 541-50.
10. Weir E. Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 2000; 162(13): 1843-8.
11. Ives T, Chelminski P, Hammett-Stabler C, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006; 6: 46.
12. Budman S, Grimes-Serrano J, Butler S. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J 2009; 6(8).
13. Butler S, Fernandez K, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med 2010; 11: 67-80.
14. Preston K, Jasinski D. Abuse liability studies of opioid agonistsantagonists in humans. Drug Alcohol Depend 1991; 28: 49-82.
15. Zacny Z, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacol 2003; 1709: 242-54.
16. Cicero T, Ellis M, Paradis A, Ortbal Z. Determinants of fentanyl and other potent mu opioid agonist misuse in opioid-dependent individuals. Pharmacoepidemiol Drug Saf 2010; 19: 1057-63.
17. Butler S, Benoit C, Budman S, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduction J 2006; 3: 5.
18. Butler S, Budman S, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-54.
19. Anon. Guidance for industry: assessment of abuse potential of drugs. Silver Spring, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research2010 January 2010.
20. Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Exp Opin Pharmacother 2009; 10(15): 2537-44.
21. O'Connor E, Mead A. Tramadol acts as a weak reinforcer in the rat self-adminstration model, consistent with its low abuse liability in humans. Pharmacol Biochem Behav 2010; 96: 279-86.
22. Pecina S, Berridge K. Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness? J Neurosci 2005; 25(50): 11777-86.
23. Pecina S, Smith K, Berridge K. Hedonic hot spots in the brain. Neuroscientist 2006; 2(6): 500-11.
24. Pecina S. Opioid reward 'liking' and 'wanting' in the nucleus accumbens. Physiol Behav 2008; 94: 675-80.
25. Berridge K, Robinson T. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998; 28: 309-69.
26. Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt L, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 2001; 34: 66-72.
27. Robinson T, Berridge K. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
28. Berridge K, Robinson T, Aldridge J. Dissecting components of reward: 'liking', 'wanting', and learning. Curr Opin Pharmacol 2009; 9: 65-73.
29. Winkielman P, Berridge K, Wilbarger J. Unconscious affective reactions to masked happy versus angry faces influence consumption behavior and judgments of value. Pers Soc Psychol Bull 2005; 31: 121-35.
30. Zacny J. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend 2005; 80: 273-8.
31. Walsh S, Nuzzo P, Lofwall M, Holtman J. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 2008; 98: 191-202.
32. Abelson J, Treloar C, Crawford J, Kippax S, vanBeek I, Howard J. Some characteristics of early-onset injection drug users prior to and at the time of their first injection. Addiction 2006; 101: 548-55.
33. Cone E. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006; 83S: S31-S9.
34. Hays L. A profile of OxyContin addiction. J Addict Dis 2004; 23(4): 1-9.
35. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009; 10(S2): S124-S33.
36. Anon. Everything U need to know about Opana and plugging. Opiophile; 2007 [cited 2011 31 March]; Available from: http://forum.opiophile.org/showthread.php?6801-Everything-U-needto-know-about-Opana-and-plugging.
37. Topp L, Day C, Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend 2003; 70(3): 275-86.
38. Maher L, Li J, Jalaludin B, et al. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Austrlian. Drug Alcohol Depend 2007; 89: 244-50.
39. Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1999; 86: 1601-6.
40. Mansbach R, Moore R. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend 2006; 83(Suppl 1): S15-S22.
41. Abreu M, Bigelow G, Fleisher L, Walsh S. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacol 2001; 154: 76-84.
42. Shram M, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010; 30: 25-33.
43. Stoops W, Hatton K, Lofwall M, Nuzzo P, Walsh S. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacol 2010; 212: 193-203.
44. Chait L, Burke K. Preference for high-versus low-potency marijuana. Pharmacol Biochem Behav 1994; 49: 643-7.
45. Stitzer M, McCaul M, Bigelow G, Liebson I. Oral methadone selfadministration: effects of dose and altnerative reinforcers. Clin Pharmacol Ther 1983; 34: 29-35.
46. Wilsey B, Fishman S, Li C-S, Storment J, Albanese A. Markers of abuse liability of short-vs long-acting opioids in chronic pain patients: a randomized, cross-over trial. Pharmacol Biochem Behav 2009; 94: 98-107.
47. Fudala P, Johnson R. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006; 83S: S40-S7.
48. Katz N, Houle B, Fernandez K, et al. Update on prescription monitoring in clinical practice: a suvey study of prescription monitoring program administrators. Pain Med 2008; 9(5): 587-94.
49. Brushwood D. Maximizing the value of electronic prescription monitoring programs. J Law Med Ethics 2003; 31: 41-54.
50. Adams E, Breiner S, Cicero T, Geller A, Inciardi J, Schnoll S, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006; 31(5): 465-76.
51. Baum C, Hsu J, Nelson R. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987; 102(4): 426-9.
52. Swift J, Hargreaves K. Pentazocine analgesia: is there a niche for Talwin Nx? Compendium 1993; 14(8): 1048.
53. Anon. Suboxone package insert. Richmond, VA: Reckitt Benckiser Pharmaceuticals, Inc.2006.
54. Passik S. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009; 84(7): 593-601.
55. Katz N, Adams E, Benneyan J, Birnbaum H, Budman S, Buzzeo R, et al. Foundations of opioid risk management. Clin J Pain 2007; 23(2): 103-18.
56. Harmonik. The impatient junkie OP spoon-crisping guide. Opiophile; 2010 [cited 2011 April 14]; Available from: http://forum.opiophile.org/archive/index.php/t-32713.html.
57. Volkow N, McLellan T. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305(13): 1346-7.
58. Richard J, Reidenberg M. The risk of disciplinary action by state medical boards against physicians prescribing opioids. J Pain Symptom Manage 2005; 29(2): 206-12.